Observational cohort study of clinical outcome in Epstein-Barr virus associated gastric cancer patients.

ABSTRACT:

Background

Epstein-Barr virus-associated gastric cancer (EBVaGC) has unique clinicopathologic features and our present understanding of its treatment outcome is limited. Here, we investigated the clinical outcomes of resectable and metastatic EBVaGC cases with regards to their respective treatment.

Methods

We retrieved the data of EBVaGC patients treated at our center from October 2014 to June 2019. The primary endpoint was overall survival (OS). Secondary endpoints were disease-free survival (DFS) for stage I-III patients, progression-free survival (PFS) and objective response rate (ORR) for stage IV patients.

Results

Patients classified as stage I-III accounted for 83.7% of the total 197 cases analyzed. Two patients had mismatched repair-deficiency. The 5-year OS ra

SUBMITTER: Qiu MZ 

PROVIDER: S-EPMC7338646 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature